Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?
详细信息 查看全文
- 作者：Aaron Brant ; B.S.a ; abrant@jhmi.edu ; Max Kates ; M.D.a ; Meera R. Chappidi ; B.A. ; B.S.a ; Hiten D. Patel ; M.D. ; M.P.H.a ; Nikolai A. Sopko ; M.D. ; Ph.D.a ; George J. Netto ; M.D.a ; Alex S. Baras ; M.D. ; Ph.D.b ; Noah M. Hahn ; M.D.b ; c ; Phillip M. Pierorazio ; M.D.a ; Trinity J. Bivalacqua ; M.D. ; Ph.D.a
- 关键词：Bladder cancer ; Radical cystectomy ; TURBT ; Neoadjuvant chemotherapy
- 刊名：Urologic Oncology: Seminars and Original Investigations
- 出版年：2017
- 出版时间：January 2017
- 年：2017
- 卷：35
- 期：1
- 页码：34.e17-34.e25
- 全文大小：612 K
- 卷排序：35
文摘
We estimate that 38% of pathologic response in patients who receive NAC for muscle-invasive bladder cancer can be attributed to TURBT. Patients who progressed from non-muscle invasive cancer were less likely to respond to TURBT. Identifying which patients respond to NAC and which respond to TURBT is needed to improve the effectiveness of both interventions.